On behalf of my co‐authors, I would like to thank you for the opportunity to reply to Dr. Altundag\'s letter \[[1](#onco12150-bib-0001){ref-type="ref"}\] submitted in reference to our manuscript, *Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor‐Positive/HER2‐Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo‐Controlled, Phase III Study (PALOMA‐3)* \[[2](#onco12150-bib-0002){ref-type="ref"}\]. Dr. Altundag commented that in PALOMA‐3, premenopausal patients were treated with fulvestrant without the addition of an ovarian suppression therapy (i.e., luteinizing hormone‐releasing hormone \[LHRH\] agonist). However, patients who were pre/perimenopausal (*n* = 108) were treated with ovarian suppression with goserelin in both arms of the study, as noted in our publication \[[1](#onco12150-bib-0001){ref-type="ref"}\] and earlier publications \[[3](#onco12150-bib-0003){ref-type="ref"}\], \[[4](#onco12150-bib-0004){ref-type="ref"}\]. These PALOMA‐3 publications provided full details regarding treatment with goserelin in pre/perimenopausal women \[[3](#onco12150-bib-0003){ref-type="ref"}\], \[[4](#onco12150-bib-0004){ref-type="ref"}\]. Specifically, all pre/perimenopausal women had to have commenced treatment with a LHRH agonist ≥4 weeks prior to randomization, with goserelin then administered every 28 days throughout the duration of study treatment \[[3](#onco12150-bib-0003){ref-type="ref"}\], \[[4](#onco12150-bib-0004){ref-type="ref"}\].

In his letter to the editors, Dr. Altundag expressed interest in more detailed safety analyses in premenopausal women. We recognize the importance of further understanding the safety profile of palbociclib in this important subgroup of patients and have, thus, performed a more in‐depth study of the safety and efficacy of palbociclib in combination with fulvestrant in pre/perimenopausal women with metastatic breast cancer in the PALOMA‐3 study. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2016 \[[5](#onco12150-bib-0005){ref-type="ref"}\] and are being prepared for publication as a manuscript. Briefly, preliminary results presented at ASCO reported that despite the concurrent use of goserelin, the safety profile of palbociclib plus fulvestrant in pre/perimenopausal women was similar to the safety profile in postmenopausal women \[[4](#onco12150-bib-0004){ref-type="ref"}\]. The frequency of adverse events (AEs) (any grade and grade 3/4) and serious AEs (any grade and grade 3/4) was similar in both groups \[[5](#onco12150-bib-0005){ref-type="ref"}\]. Also, rates of discontinuations and dose modifications due to AEs were similar in pre/perimenopausal and postmenopausal women \[[5](#onco12150-bib-0005){ref-type="ref"}\]. Further details on the safety profile of palbociclib in premenopausal breast cancer patients in PALOMA‐3 will be described in a future publication.
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**For Further Reading:** Sunil Verma, Cynthia Huang Bartlett, Patrick Schnell et al. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor‐Positive/HER2‐Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo‐Controlled, Phase III Study (PALOMA‐3). ***The Oncologist*** 2016;21:1165--1175.

**Implications for Practice:** Treatment with palbociclib in combination with fulvestrant was generally safe and well‐tolerated in patients with hormone receptor (HR)‐positive metastatic breast cancer. Consistent with the drug\'s proposed mechanism of action, palbociclib‐related neutropenia differs in its clinical time course, patterns, and consequences from those seen with chemotherapy. Neutropenia can be effectively managed by a dose reduction, interruption, or cycle delay without compromising efficacy. A significant efficacy gain and a favorable safety profile support the consideration of incorporating palbociclib into the routine management of HR‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer.
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